Navigation Links
Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
Date:9/16/2010

KALAMAZOO, Mich., Sept. 16 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC), www.msdrx.com, will present research at the European Association for the Study of Diabetes (EASD) annual conference in Stockholm, Sweden on Sept. 23, 2010.  The research indicates that the company's clinical candidate, MSDC-0160, promotes the proliferation of stem cells that create brown fat, leading to the creation of more brown fat.  The research was conducted in tissue cultures and mice.

Numerous scientific studies have shown that the amount of brown adipose tissue (commonly known as "brown fat") in the human body is an important factor in determining if calories are burned as energy or stored as fat. 

"Lean people have more brown fat than individuals who are obese," said Jerry Colca, president and chief scientific officer of MSDC.  "The amount of brown fat in the body decreases as an individual ages, particularly in men. If a person had more brown fat, that individual would be better able to lose weight."  

"Our clinical candidates (including MSDC-0160) promote the proliferation of brown fat tissue from stem cells through cellular differentiation," said Rolf Kletzien, senior MSDC author on the study. 

"The ability of our clinical candidates to activate a novel biochemical pathway may provide additional insight and understanding into the mechanism by which they lower blood glucose in human patients without causing weight gain," added Kletzien.

Pharmaceuticals that impact a human's ability to produce brown fat may provide a new means to treat diseases related to excess body weight and cardiometabolic syndrome.

MSDC is a drug development company that is creating and testing a series of pharmaceutical candidates designed to treat type 2 diabetes more effectively without the side effects of current therapies.  

An MSDC Phase 2a clinical trial of MSDC-0160 demonstrated that it improves insulin sensitivity and lowers blood glucose levels in humans without the side effects of the current market-leading diabetes medicines. The compound also demonstrated significant improvements in other important metabolic disease risk factors including blood pressure and lipids.  

About Metabolic Solutions Development Company:Metabolic Solutions Development Company (www.msdrx.com), based in Kalamazoo, Mich., is developing innovative therapeutics using a different pharmacological path to treat type 2 diabetes. This new approach seeks to improve the efficacy of treatment by freeing patients from the adverse side effects of current treatments, including edema and weight gain.

The company's scientific strategy is built on a historical understanding of insulin-sensitizers and its unique insight into the mechanism of insulin-sensitizing pharmacology. The company believes that the result will be a new generation of superior, safer drug therapies.CONTACT:Nick WasmillerSeyferthPR1-800-435-9539wasmiller@seyferthpr.com
'/>"/>

SOURCE Metabolic Solutions Development Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development
2. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
3. Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence
4. Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28
5. Reportlinker Adds Metabolic Endocrinology Hypocalcemia
6. Metabolic Solutions Development Company To Test Potential Treatment for Alzheimers
7. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
8. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
9. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
10. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
11. Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidones Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC ... Equipment Manufacturer (OEM) Board to enable seamless integration ... patient monitoring systems, infusion pumps and other devices. ... will be able to help health care customers ... reduced risks related to IV therapy. ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... ... servicing communities throughout the greater Cincinnati metropolitan area, is teaming up with the ... for families with children receiving treatment in nearby hospitals. , Ronald McDonald House ...
(Date:6/27/2017)... ... June 27, 2017 , ... Harbour , a DAO (decentralized ... the Ethereum blockchain, has released their technical specifications . , 2017 has seen ... little systematic approach for determining which offerings will garner the greatest ROI. Dean Eigenmann, ...
(Date:6/27/2017)... NY (PRWEB) , ... June 27, 2017 , ... From ... members. The three-day event was held in Syracuse, New York, where EarQ is headquartered. ... changing industry, how to connect with today’s savvy consumer, and the latest in ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR News is looking for ... guidebook. This guidebook offers an excellent branding and exposure opportunity for the author ... and how-to’s that fall into the following categories:, ,     Media ...
(Date:6/27/2017)... ... June 27, 2017 , ... Hammer Strength, the world’s leading performance ... Javair Gillett of the Houston Rockets the NBSCA Strength & Conditioning Coach of the ... by NBSCA members who vote to select the coach who embodies the highest level ...
Breaking Medicine News(10 mins):